Developer docs
API playgroundTry for free, no card

Search company profiles

Orange Grove Bio

Full company profile

uuid00026sp

Namestring
Orange Grove Bio
Legal namestring
Orange Grove Bio LLC
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Orange Grove Bio (legal entity Orange Grove Bio LLC, also referenced as OGB) is a private, Cincinnati-based biotech holding and company-creation platform founded in 2019. The firm identifies promising early-stage academic research from U.S. regions underserved by traditional venture capital — specifically the Southeast, Midwest, and Mid-Atlantic — as well as from South Korea and Israel, and forms majority-owned subsidiaries that license in foundational intellectual property from those universities. Its portfolio of six disclosed companies (five active) spans small-molecule immunoproteasome inhibitors (IpiNovyx Bio), TGF-beta pathway modulators for fibrosis (DomainOne Therapeutics), non-viral gene therapy for cystic fibrosis (Genexys BioMed), small molecules for inflammatory bowel disease and metabolic disease (Allonix Therapeutics), ex vivo platelet preservation additives (Preservation Bio), and neutrophil-targeted drug delivery for inflammatory disease (Asalyxa Bio).

The operating model combines in-house drug-development capabilities — including medicinal chemistry, CMC, translational biology, regulatory affairs, and venture operations — with academic sourcing relationships. Orange Grove Bio provides both scientific and financial support to portfolio entities, which retain the licensed IP, and positions them for licensing, co-development, or acquisition by pharmaceutical partners. The platform has secured notable non-dilutive capital for portfolio companies, including a $2.05 million NIH SBIR Phase II grant for Preservation Bio and a $320,000 Phase I SBIR for Genexys BioMed, alongside strategic equity rounds (IpiNovyx's $10M seed led by Viva BioInnovator with Eli Lilly participation). Strategic partnerships with institutions such as the University of Chicago, University of Pittsburgh, Dartmouth, Einstein, Weizmann/Bina, Yonsei, and POSTECH extend the sourcing network.

Orange Grove Bio monetizes through equity ownership in portfolio companies and milestone economics tied to licensing, co-development, or acquisition transactions with pharmaceutical companies, rather than direct product sales. It has raised a 2025 round from a Denver-based investor consortium and operates with 11-50 employees under a leadership team including CEO Salvatore Cremona (appointed August 2025), President & General Counsel Garin Murphy, and CFO David Crampton. All portfolio programs remain preclinical, with IpiNovyx targeting clinical entry around mid-2026.

Short descriptiontext

Orange Grove Bio is a Cincinnati-based biotech company-creation platform that sources academic research from underserved U.S. regions and abroad, forms majority-owned subsidiaries around licensed IP, and develops preclinical therapeutics in oncology, autoimmune, inflammatory, fibrotic, and rare genetic diseases for eventual pharma partnership or acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCincinnati, United States
HQ citystring
Cincinnati
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical drug development, biotech investment platform, academic technology licensing, company creation platform, pharmaceutical partnerships
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Development and Biotech Investment Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Company Creation and Equity Ownership
TypeLicensing Royalties
Description

Orange Grove Bio creates new biotech companies from academic research, retaining equity ownership. The company generates returns when portfolio companies are acquired, go public, or achieve milestones through partnerships with pharmaceutical companies.

orangegrovebio.com
2Strategic Partnerships with Pharma
TypeLicensing Royalties
Description

Partnerships with pharmaceutical companies for co-development, licensing, and commercialization of therapeutic candidates developed through the platform.

orangegrovebio.com
3NIH Grant Funding
TypeProfessional Services
Description

Portfolio companies receive NIH SBIR grants to advance specific technologies (e.g., Preservation Bio's $2.05M SBIR Phase II grant, Genexys BioMed's $320K Phase 1 SBIR grant).

orangegrovebio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Orange Grove Bio is a preclinical drug investment and development platform that identifies promising academic research in non-traditional venture capital regions (Southeast, Midwest, Mid-Atlantic) and creates majority-owned biotech portfolio companies to advance those discoveries toward clinical development. The company then partners with or sells those portfolio companies to pharmaceutical companies, retaining equity and earning returns via licensing, milestones, and exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Extended platelet shelf life from 5-7 days to 14 days, potentially reducing 10-15% platelet waste
+2 more records
Product overview1 text field

Orange Grove Bio is a biotech holding company and company creation platform that identifies, invests in, and develops early-stage therapeutic candidates. The platform operates across five therapeutic focus areas: oncology, autoimmune diseases, inflammatory diseases, fibrosis, and rare genetic disorders. The company has launched seven portfolio companies including Allonix Therapeutics (small molecules for IBD/metabolic disease), DomainOne Therapeutics (TGF-beta inhibitors for fibrosis), Genexys BioMed (non-viral gene therapy for cystic fibrosis), IpiNovyx Bio (proteasome inhibitors for autoimmune/inflammatory diseases), Preservation Bio (platelet preservation additives for transfusion medicine), and Asalyxa Bio (neutrophil-targeted drug delivery). Orange Grove Bio provides scientific expertise, financial support, and operational capabilities to translate discoveries from academic research into clinical-stage therapies.

Product and service6 records
1IpiNovyx Bio
CategoryPortfolio Company - Therapeutic Development
Description

Pre-clinical stage biopharmaceutical company (majority-owned portfolio company) developing next-generation, highly selective reversible small molecule inhibitors of the immunoproteasome for the treatment of oncology, autoimmune, and inflammatory diseases. Lead program targeted at clinical entry mid-2026.

2Preservation Bio
CategoryPortfolio Company - Therapeutic Development
Description

Pre-clinical stage company (majority-owned portfolio company) developing an ex vivo platelet additive that protects platelets from cold storage damage, extends shelf life from 5-7 days to 14 days under refrigeration, reduces bacterial contamination risk, and addresses platelet shortage in the blood supply chain.

3Genexys BioMed
CategoryPortfolio Company - Therapeutic Development
Description

Pre-clinical stage company (majority-owned portfolio company) developing a novel non-viral, non-lipid gene therapy platform for cystic fibrosis treatment. Delivers therapeutic mRNA/DNA directly to patient lungs using organic polymer-based technology, designed to work for all CF patients regardless of CFTR mutation.

4Allonix Therapeutics
CategoryPortfolio Company - Therapeutic Development
Description

Pre-clinical stage company (majority-owned portfolio company) developing novel small molecule drugs that target a cell-signaling pathway implicated in inflammation, cholesterol homeostasis, and cellular metabolism. Lead program aims to treat inflammatory bowel disease (IBD) through a unique mechanism of action, with pipeline potential for diabetes, obesity, and cancers.

5DomainOne Therapeutics
CategoryPortfolio Company - Therapeutic Development
Description

Pre-clinical stage company (majority-owned portfolio company) developing small molecule inhibitors modulating the TGF-beta pathway to treat fibrosis. Initial focus on fibrotic diseases affecting liver, lungs, heart, and kidneys by targeting thrombospondin 1 (TSP1) Domain One to inhibit TGF-beta activation.

6Asalyxa Bio
CategoryPortfolio Company - Therapeutic Development
Description

First portfolio company (now inactive) developing nano-engineered, immune cell-targeted therapeutics using the PANTHER platform. Lead program ASX-100 delivered anti-inflammatory agents directly to overreactive neutrophils for treatment of Acute Respiratory Distress Syndrome (ARDS) and inflammatory diseases.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-23
Description

Strategic partnership to catalyze commercialization of novel therapeutics and life sciences technologies. Orange Grove will license promising technologies from UChicago and establish presence on South Side of Chicago.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-23
Description

Partnership to strengthen biotech entrepreneurial ecosystem in South Korea. Orange Grove will support translation of scientific discoveries and company creation in oncology and autoimmune/inflammatory diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-23
Description

Partnership to strengthen biotech entrepreneurial ecosystem in South Korea through educational programming and company creation support in oncology and autoimmune/inflammatory diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-31
Description

Collaboration with Bina, the translational research unit of Weizmann Institute, to tap into the biotech ecosystem in the Middle East. Orange Grove will guide and mentor early-stage research, identify opportunities for company creation, and implement graduate internship programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-10
Description

Collaboration to strengthen biotech ecosystem and support commercialization of novel therapeutics. Includes PhD internship program and Orange Grove team serving as Entrepreneur in Residence.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-17
Description

Collaboration to advance development and commercialization of novel therapeutics by supporting translation of discoveries in oncology and autoimmune/inflammatory diseases. Includes PhD internships for Pitt students.

7Albert Einstein College of Medicine
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-21
Description

Partnership with Einstein, AlleyCorp, and Alexandria Venture Investments to support development of novel therapeutics. Einstein scientists receive mentorship and financial support to advance research into new drug candidates.

orangegrovebio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Crohn's & Colitis Foundation for Allonix Therapeutics, the leading non-profit organization in IBD space. The Foundation's IBD Ventures group has invested in Allonix.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Source of multiple technologies including Genexys BioMed's gene therapy platform and Preservation Bio's platelet storage technology. Dr. Assem Ziady's lab at Cincinnati Children's developed the gene therapy technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Source of Preservation Bio's platelet storage technology. Dr. Jose Cancelas and Dr. Yi Zheng led research at University of Cincinnati and Cincinnati Children's Hospital Medical Center.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Source of DomainOne Therapeutics' TGF-beta inhibitor technology, developed in partnership with Southern Research Institute.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in DomainOne Therapeutics alongside University of Alabama for development of TGF-beta pathway inhibitors for fibrosis treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Source of IpiNovyx Bio's proteasome inhibitor technology from labs of Gang Lin and Carl Nathan at Weill Cornell Medicine.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Source of IpiNovyx Bio's technology from lab of Franck Barrat at Hospital for Special Surgery Research Institute.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Source of Allonix Therapeutics' foundational science from pioneering work by Eric Ortlund and Dr. John Calvert at Emory University.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site for Preservation Bio's Phase 1 clinical trial in Cincinnati.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest biotech company-creation platform; launches and incubates subsidiary biotechs (Vants) around specific therapeutic assets and exits via pharma partnerships or spinouts — the closest operational analogue to Orange Grove Bio's model.

TypeDirect peer
Description

Clinical-stage biotherapeutics company creation platform that identifies academic discoveries and develops them through majority-owned subsidiaries — closely matches Orange Grove Bio's holding-company structure and academic-sourcing strategy.

TypeDirect peer
Description

Biotech that builds subsidiaries around genetically validated disease targets sourced from academic research; comparable in building multiple parallel programs with pharma partnership as a key exit vector.

TypeBroad incumbent
Description

Largest biotech platform creating companies from scientific concepts; similar company-creation model with much greater scale and capital base (founded Moderna, Generate Biomedicines).

TypeDirect peer
Description

Biotech venture capital firm that both finances and builds biotech companies around academic and emerging biopharma assets — closely mirrors Orange Grove Bio's build-and-partner model.

TypeDirect peer
Description

Early-stage biotech venture firm that forms and incubates new companies from academic science with experienced pharma operators; comparable in building and seeding preclinical biotechs.

TypeBroad incumbent
Description

Healthcare-focused investment firm with significant academic partnership and company-creation capabilities across therapeutics; broader scale and capital than Orange Grove Bio but overlapping sourcing model.

8Cedilla Therapeutics (now part of Lilly)
TypeEmerging player
Description

Pre-clinical biotech focused on targeted protein degradation, originated from academic science at Princeton — illustrates the academic-sourcing and pharma-exit pathway Orange Grove Bio pursues for its portfolio.

TypeEmerging player
Description

Biotech developing small molecule therapeutics for inflammatory diseases (similar to Allonix's IBD focus) — comparable as a portfolio-company-scale asset within a similar sourcing and development model.

TypeOthers
Description

Orange Grove Bio's own first portfolio company developing neutrophil-targeted therapeutics for ARDS/inflammation — included to illustrate the type of spinout the platform creates rather than as an external competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orange Grove Bio

Preclinical Drug Development and Biotech Investment Platformorangegrovebio.com

Orange Grove Bio is a Cincinnati-based biotech company-creation platform that sources academic research from underserved U.S. regions and abroad, forms majority-owned subsidiaries around licensed IP, and develops preclinical therapeutics in oncology, autoimmune, inflammatory, fibrotic, and rare genetic diseases for eventual pharma partnership or acquisition.

What Orange Grove Bio does

Orange Grove Bio (legal entity Orange Grove Bio LLC, also referenced as OGB) is a private, Cincinnati-based biotech holding and company-creation platform founded in 2019. The firm identifies promising early-stage academic research from U.S. regions underserved by traditional venture capital — specifically the Southeast, Midwest, and Mid-Atlantic — as well as from South Korea and Israel, and forms majority-owned subsidiaries that license in foundational intellectual property from those universities. Its portfolio of six disclosed companies (five active) spans small-molecule immunoproteasome inhibitors (IpiNovyx Bio), TGF-beta pathway modulators for fibrosis (DomainOne Therapeutics), non-viral gene therapy for cystic fibrosis (Genexys BioMed), small molecules for inflammatory bowel disease and metabolic disease (Allonix Therapeutics), ex vivo platelet preservation additives (Preservation Bio), and neutrophil-targeted drug delivery for inflammatory disease (Asalyxa Bio).

The operating model combines in-house drug-development capabilities — including medicinal chemistry, CMC, translational biology, regulatory affairs, and venture operations — with academic sourcing relationships. Orange Grove Bio provides both scientific and financial support to portfolio entities, which retain the licensed IP, and positions them for licensing, co-development, or acquisition by pharmaceutical partners. The platform has secured notable non-dilutive capital for portfolio companies, including a $2.05 million NIH SBIR Phase II grant for Preservation Bio and a $320,000 Phase I SBIR for Genexys BioMed, alongside strategic equity rounds (IpiNovyx's $10M seed led by Viva BioInnovator with Eli Lilly participation). Strategic partnerships with institutions such as the University of Chicago, University of Pittsburgh, Dartmouth, Einstein, Weizmann/Bina, Yonsei, and POSTECH extend the sourcing network.

Orange Grove Bio monetizes through equity ownership in portfolio companies and milestone economics tied to licensing, co-development, or acquisition transactions with pharmaceutical companies, rather than direct product sales. It has raised a 2025 round from a Denver-based investor consortium and operates with 11-50 employees under a leadership team including CEO Salvatore Cremona (appointed August 2025), President & General Counsel Garin Murphy, and CFO David Crampton. All portfolio programs remain preclinical, with IpiNovyx targeting clinical entry around mid-2026.

Orange Grove Bio firmographics

Firmographics
Name
Orange Grove Bio
Legal name
Orange Grove Bio LLC
Website
https://orangegrovebio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Orange Grove Bio is a Cincinnati-based biotech company-creation platform that sources academic research from underserved U.S. regions and abroad, forms majority-owned subsidiaries around licensed IP, and develops preclinical therapeutics in oncology, autoimmune, inflammatory, fibrotic, and rare genetic diseases for eventual pharma partnership or acquisition.
Ownership category
akta.pro rank

Orange Grove Bio industry classification

Industry
Product category
Preclinical Drug Development and Biotech Investment Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Preclinical drug development
  • Biotech investment platform
  • Academic technology licensing
  • Company creation platform
  • Pharmaceutical partnerships

Where Orange Grove Bio is headquartered

Location

Headquarters

HQ city
Cincinnati
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Orange Grove Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Company Creation and Equity Ownership: Orange Grove Bio creates new biotech companies from academic research, retaining equity ownership. The company generates returns when portfolio companies are acquired, go public, or achieve milestones through partnerships with pharmaceutical companies.
  2. Strategic Partnerships with Pharma: Partnerships with pharmaceutical companies for co-development, licensing, and commercialization of therapeutic candidates developed through the platform.
  3. NIH Grant Funding: Portfolio companies receive NIH SBIR grants to advance specific technologies (e.g., Preservation Bio's $2.05M SBIR Phase II grant, Genexys BioMed's $320K Phase 1 SBIR grant).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Orange Grove Bio product offering

Product offering

Core offering

Orange Grove Bio is a preclinical drug investment and development platform that identifies promising academic research in non-traditional venture capital regions (Southeast, Midwest, Mid-Atlantic) and creates majority-owned biotech portfolio companies to advance those discoveries toward clinical development. The company then partners with or sells those portfolio companies to pharmaceutical companies, retaining equity and earning returns via licensing, milestones, and exits.

Product overview

Orange Grove Bio is a biotech holding company and company creation platform that identifies, invests in, and develops early-stage therapeutic candidates. The platform operates across five therapeutic focus areas: oncology, autoimmune diseases, inflammatory diseases, fibrosis, and rare genetic disorders. The company has launched seven portfolio companies including Allonix Therapeutics (small molecules for IBD/metabolic disease), DomainOne Therapeutics (TGF-beta inhibitors for fibrosis), Genexys BioMed (non-viral gene therapy for cystic fibrosis), IpiNovyx Bio (proteasome inhibitors for autoimmune/inflammatory diseases), Preservation Bio (platelet preservation additives for transfusion medicine), and Asalyxa Bio (neutrophil-targeted drug delivery). Orange Grove Bio provides scientific expertise, financial support, and operational capabilities to translate discoveries from academic research into clinical-stage therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • IpiNovyx Bio Pre-clinical stage biopharmaceutical company (majority-owned portfolio company) developing next-generation, highly selective reversible small molecule inhibitors of the immunoproteasome for the treatment of oncology, autoimmune, and inflammatory diseases. Lead program targeted at clinical entry mid-2026.
  • Preservation Bio Pre-clinical stage company (majority-owned portfolio company) developing an ex vivo platelet additive that protects platelets from cold storage damage, extends shelf life from 5-7 days to 14 days under refrigeration, reduces bacterial contamination risk, and addresses platelet shortage in the blood supply chain.
  • Genexys BioMed Pre-clinical stage company (majority-owned portfolio company) developing a novel non-viral, non-lipid gene therapy platform for cystic fibrosis treatment. Delivers therapeutic mRNA/DNA directly to patient lungs using organic polymer-based technology, designed to work for all CF patients regardless of CFTR mutation.
  • Allonix Therapeutics Pre-clinical stage company (majority-owned portfolio company) developing novel small molecule drugs that target a cell-signaling pathway implicated in inflammation, cholesterol homeostasis, and cellular metabolism. Lead program aims to treat inflammatory bowel disease (IBD) through a unique mechanism of action, with pipeline potential for diabetes, obesity, and cancers.
  • DomainOne Therapeutics Pre-clinical stage company (majority-owned portfolio company) developing small molecule inhibitors modulating the TGF-beta pathway to treat fibrosis. Initial focus on fibrotic diseases affecting liver, lungs, heart, and kidneys by targeting thrombospondin 1 (TSP1) Domain One to inhibit TGF-beta activation.
  • Asalyxa Bio First portfolio company (now inactive) developing nano-engineered, immune cell-targeted therapeutics using the PANTHER platform. Lead program ASX-100 delivered anti-inflammatory agents directly to overreactive neutrophils for treatment of Acute Respiratory Distress Syndrome (ARDS) and inflammatory diseases.

Quantifiable outcome

  • Extended platelet shelf life from 5-7 days to 14 days, potentially reducing 10-15% platelet waste
  • +2 more outcomes

Companies that use Orange Grove Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Orange Grove Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Orange Grove Bio partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • University of Chicago (Polsky Center)coreStrategic or Co-development Partner · 23 July 2024Strategic partnership to catalyze commercialization of novel therapeutics and life sciences technologies. Orange Grove will license promising technologies from UChicago and establish presence on South Side of Chicago.
  • Yonsei University Health SystemcoreStrategic or Co-development Partner · 23 March 2023Partnership to strengthen biotech entrepreneurial ecosystem in South Korea. Orange Grove will support translation of scientific discoveries and company creation in oncology and autoimmune/inflammatory diseases.
  • Pohang University of Science and Technology (POSTECH)coreStrategic or Co-development Partner · 23 March 2023Partnership to strengthen biotech entrepreneurial ecosystem in South Korea through educational programming and company creation support in oncology and autoimmune/inflammatory diseases.
  • Weizmann Institute of Science (Bina)coreStrategic or Co-development Partner · 31 January 2023Collaboration with Bina, the translational research unit of Weizmann Institute, to tap into the biotech ecosystem in the Middle East. Orange Grove will guide and mentor early-stage research, identify opportunities for company creation, and implement graduate internship programs.
  • Dartmouth College (Magnuson Center)coreStrategic or Co-development Partner · 10 November 2022Collaboration to strengthen biotech ecosystem and support commercialization of novel therapeutics. Includes PhD internship program and Orange Grove team serving as Entrepreneur in Residence.
  • University of PittsburghcoreStrategic or Co-development Partner · 17 November 2021Collaboration to advance development and commercialization of novel therapeutics by supporting translation of discoveries in oncology and autoimmune/inflammatory diseases. Includes PhD internships for Pitt students.
  • Albert Einstein College of MedicinecoreStrategic or Co-development Partner · 21 October 2021Partnership with Einstein, AlleyCorp, and Alexandria Venture Investments to support development of novel therapeutics. Einstein scientists receive mentorship and financial support to advance research into new drug candidates.
  • Crohn's & Colitis FoundationcoreStrategic or Co-development PartnerPartnership with Crohn's & Colitis Foundation for Allonix Therapeutics, the leading non-profit organization in IBD space. The Foundation's IBD Ventures group has invested in Allonix.
  • Cincinnati Children's Hospital Medical CentercoreStrategic or Co-development PartnerSource of multiple technologies including Genexys BioMed's gene therapy platform and Preservation Bio's platelet storage technology. Dr. Assem Ziady's lab at Cincinnati Children's developed the gene therapy technology.
  • University of CincinnaticoreStrategic or Co-development PartnerSource of Preservation Bio's platelet storage technology. Dr. Jose Cancelas and Dr. Yi Zheng led research at University of Cincinnati and Cincinnati Children's Hospital Medical Center.
  • University of AlabamacoreStrategic or Co-development PartnerSource of DomainOne Therapeutics' TGF-beta inhibitor technology, developed in partnership with Southern Research Institute.
  • Southern Research InstitutecoreStrategic or Co-development PartnerPartner in DomainOne Therapeutics alongside University of Alabama for development of TGF-beta pathway inhibitors for fibrosis treatment.
  • Weill Cornell MedicinecoreStrategic or Co-development PartnerSource of IpiNovyx Bio's proteasome inhibitor technology from labs of Gang Lin and Carl Nathan at Weill Cornell Medicine.
  • Hospital for Special Surgery Research InstitutecoreStrategic or Co-development PartnerSource of IpiNovyx Bio's technology from lab of Franck Barrat at Hospital for Special Surgery Research Institute.
  • Emory UniversitycoreStrategic or Co-development PartnerSource of Allonix Therapeutics' foundational science from pioneering work by Eric Ortlund and Dr. John Calvert at Emory University.
  • Hoxworth Blood CenterminorStrategic or Co-development PartnerClinical trial site for Preservation Bio's Phase 1 clinical trial in Cincinnati.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Orange Grove Bio competitors and assessment

Company assessment

Direct peers

  • Roivant Sciences: Largest biotech company-creation platform; launches and incubates subsidiary biotechs (Vants) around specific therapeutic assets and exits via pharma partnerships or spinouts — the closest operational analogue to Orange Grove Bio's model.
  • PureTech Health: Clinical-stage biotherapeutics company creation platform that identifies academic discoveries and develops them through majority-owned subsidiaries — closely matches Orange Grove Bio's holding-company structure and academic-sourcing strategy.
  • BridgeBio Pharma: Biotech that builds subsidiaries around genetically validated disease targets sourced from academic research; comparable in building multiple parallel programs with pharma partnership as a key exit vector.
  • Apple Tree Partners: Biotech venture capital firm that both finances and builds biotech companies around academic and emerging biopharma assets — closely mirrors Orange Grove Bio's build-and-partner model.
  • Atlas Venture: Early-stage biotech venture firm that forms and incubates new companies from academic science with experienced pharma operators; comparable in building and seeding preclinical biotechs.

Broad incumbents

  • Flagship Pioneering: Largest biotech platform creating companies from scientific concepts; similar company-creation model with much greater scale and capital base (founded Moderna, Generate Biomedicines).
  • Deerfield Management: Healthcare-focused investment firm with significant academic partnership and company-creation capabilities across therapeutics; broader scale and capital than Orange Grove Bio but overlapping sourcing model.

Emerging players

  • Cedilla Therapeutics (now part of Lilly): Pre-clinical biotech focused on targeted protein degradation, originated from academic science at Princeton — illustrates the academic-sourcing and pharma-exit pathway Orange Grove Bio pursues for its portfolio.
  • Aiolos Bio: Biotech developing small molecule therapeutics for inflammatory diseases (similar to Allonix's IBD focus) — comparable as a portfolio-company-scale asset within a similar sourcing and development model.

Others

  • Asalyxa Bio: Orange Grove Bio's own first portfolio company developing neutrophil-targeted therapeutics for ARDS/inflammation — included to illustrate the type of spinout the platform creates rather than as an external competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Orange Grove Bio social profiles

Digital presence

Orange Grove Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orange Grove Bio leadership team

Management profile

Number of profiles

Profiles14 records

Orange Grove Bio subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Orange Grove Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orange Grove Bio M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orange Grove Bio

What does Orange Grove Bio do?

Orange Grove Bio is a preclinical drug investment and development platform that identifies promising academic research in non-traditional venture capital regions (Southeast, Midwest, Mid-Atlantic) and creates majority-owned biotech portfolio companies to advance those discoveries toward clinical development. The company then partners with or sells those portfolio companies to pharmaceutical companies, retaining equity and earning returns via licensing, milestones, and exits.

Is Orange Grove Bio a public or private company?

Orange Grove Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Orange Grove Bio founded?

Orange Grove Bio was founded in 2019. It employs 11 to 50 people.

Where is Orange Grove Bio based?

Orange Grove Bio is headquartered in Cincinnati, United States, in the North America region.

How does Orange Grove Bio make money?

Three revenue lines are on record. Company Creation and Equity Ownership is the primary driver. The others are strategic Partnerships with Pharma and NIH Grant Funding.

Who are Orange Grove Bio's main competitors?

Direct peers on record are Roivant Sciences, PureTech Health, BridgeBio Pharma, Apple Tree Partners and Atlas Venture. Broad incumbents are Flagship Pioneering and Deerfield Management. Emerging players are Cedilla Therapeutics (now part of Lilly) and Aiolos Bio. Asalyxa Bio is listed as an others.

Does Orange Grove Bio have an API?

No public API is recorded for Orange Grove Bio.

What industry is Orange Grove Bio in?

Orange Grove Bio's product category is Preclinical Drug Development and Biotech Investment Platform. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Polsky Center for Entrepreneurship and Innovation -Polsky Center Teams with Orange Grove Bio to Catalyze Biotech Innovation at UChicagoThe University of Chicago's Polsky Center signed a strategic agreement with Orange Grove Bio to support pipeline development, entrepreneurial training, and funding. OGB will license promising life sciences technologies from the university and lead educational programs, including a remote PhD internship. The partnership aims to advance therapeutics and strengthen Chicago's biotech ecosystem.YahooOrange Grove Bio and University of Chicago Form Strategic Partnership to Accelerate Biotech Innovation and CommercializationOrange Grove Bio and the University of Chicago's Polsky Center announced a strategic partnership to commercialize novel therapeutics. Orange Grove Bio will license promising technologies, lead a PhD internship program, and establish a South Side presence to bridge venture capital gaps.American City Business JournalsUChicago Polsky Center partners with biotech firm Orange Grove BioUChicago Polsky Center partnered with biotech firm Orange Grove Bio, which moved its headquarters to Cincinnati in 2021. The agreement includes licensing life-sciences technologies and developing them into products, plus educational workshops and a Ph.D. internship program.PR NewswireOrange Grove Bio and University of Chicago Form Strategic Partnership to Accelerate Biotech Innovation and CommercializationOrange Grove Bio and the University of Chicago's Polsky Center announced a strategic partnership to commercialize novel therapeutics. Orange Grove Bio will license promising technologies and lead a PhD internship program, and plans to establish a South Side Chicago presence. The collaboration aims to bridge venture capital gaps and accelerate translation of research into treatments.GlobeNewswireOrange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of ScienceOrange Grove Bio announced a strategic collaboration with Bina, the translational research unit of the Weizmann Institute of Science, to tap into the Middle East's biotech ecosystem. The partnership includes a memorandum of understanding and will guide early-stage research, with Orange Grove mentoring and providing internship programs.GlobeNewswireOrange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of ScienceOrange Grove Bio announced a strategic collaboration with Bina, the translational research unit of the Weizmann Institute of Science, to tap into the Middle East's biotech ecosystem. The partnership includes a memorandum of understanding and will guide early-stage research, with Orange Grove mentoring and providing internship programs.OrangegrovebioOrange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation TechnologyPreservation Bio, a subsidiary of Orange Grove Bio, received a $2.05 million SBIR Phase II grant from the National Heart, Lung, and Blood Institute to develop a novel platelet preservation technology. The funding will support the advancement of an additive that allows donated platelets to be stored at refrigeration temperatures for up to 14 days, potentially doubling their current shelf life.GlobeNewswireOrange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation TechnologyPreservation Bio, a subsidiary of Orange Grove Bio, received a $2.05 million SBIR Phase II grant from the NIH to advance platelet preservation technology. The funding will support development of G04, a small molecule that could enable refrigerated storage of platelets for up to 14 days. Orange Grove Bio also announced new senior advisor appointments and opened its new headquarters in Cincinnati.GlobeNewswireOrange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation TechnologyOrange Grove Bio's subsidiary, Preservation Bio, was awarded a $2.05 million SBIR Phase II grant by the National Heart, Lung, and Blood Institute on September 28, 2023, to develop a method for preserving donated platelets effectively. This technology aims to extend the shelf life of platelets to over 14 days, addressing a critical shortage in the healthcare sector and potentially transforming blood banking practices. The grant funding will support the continued preclinical development of Preservation Bio's innovative G04 solution for platelet storage.